期刊文献+

Mortality and health care burden of Budd Chiari syndrome in the United States:A nationwide analysis(1998-2017) 被引量:1

下载PDF
导出
摘要 The Budd Chiari syndrome(BCS)is a rare and potentially fatal disease,but there is a paucity of data on the in-hospital mortality as well its economic burden on the health care system.AIM To evaluate trends in mortality,length of hospital stays and resource utilization among inpatients with BCS.METHODS Data on all adult patients with a diagnosis of BCS were extracted from the National Inpatient Sample(NIS)from 1998 to 2017.To make inferences regarding the national estimates for the total number of BCS discharges across the study period,sample weights were applied to each admission per recommendations from the NIS.RESULTS During the study period,there were 3591(8.73%)in-patient deaths.The overall inhospital mortality rates among BCS patients decreased from 18%in 1998 to 8%in 2017;the mortality decreased by 4.41%(P<0.0001)every year.On multivariate analysis,older age,higher comorbidity score,acute liver failure,acute kidney injury,acute respiratory failure,hepatic encephalopathy,hepatorenal syndrome,inferior vena cava thrombosis,intestinal infarct,sepsis/septic shock and cancer were associated increased risk of mortality.The average of length of stay was 8.8 d and it consistently decreased by 2.04%(95%CI:-2.67%,-1.41%,P<0.001)from 12.7 d in 1998 to 7.6 d in 2017.The average total charges after adjusted for Medical Care Consumers Price Index to 2017 dollars during the time period was$94440 and the annual percentage change increased by 1.15%(95%CI:0.35%,1.96%,P=0.005)from$95515 in 1998 to$103850 in 2017.CONCLUSION The in-hospital mortality rate for patients admitted with BCS in the United States has reduced between 1998 and 2017 and this may a reflection of better management of these patients.
出处 《World Journal of Hepatology》 2021年第6期686-698,共13页 世界肝病学杂志(英文版)(电子版)
  • 相关文献

参考文献1

二级参考文献11

  • 1Andrea Mancuso.Budd-Chiari syndrome management:Lights and shadows[J].World Journal of Hepatology,2011,3(10):262-264. 被引量:6
  • 2Dominique-Charles Valla.Primary Budd-Chiari syndrome[J].Journal of Hepatology.2008(1)
  • 3DOMINIQUE‐CHARLESVALLA.Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West[J].Journal of Gastroenterology and Hepatology.2004
  • 4Andrea Mancuso.TIPS for Budd–Chiari syndrome: time to anticipate treatment[J].Liver Int.2014(7)
  • 5Katerina Fitsiori,Maria Tsitskari,Alexios Kelekis,Dimitrios Filippiadis,Konstantinos Triantafyllou,Elias Brountzos.Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Budd–Chiari Syndrome Patients: Results From a Single Center[J].CardioVascular and Interventional Radiology.2014(3)
  • 6D. Tripathi,R. MacNicholas,C. Kothari,L. Sunderraj,H. Al‐Hilou,B. Rangarajan,F. Chen,K. Mangat,E. Elias,S. Olliff.Good clinical outcomes following transjugular intrahepatic portosystemic stent‐shunts in Budd–Chiari syndrome[J].Aliment Pharmacol Ther.2014(8)
  • 7J.K. Banerjee.Portal hypertension[J].Medical Journal Armed Forces India.2012(3)
  • 8Juan Carlos Garcia–Pagán,Mathis Heydtmann,Sebastian Raffa,Aurélie Plessier,Sarwa Murad,Federica Fabris,Giovanni Vizzini,Juan Gonzales Abraldes,Simon Olliff,Antonio Nicolini,Angelo Luca,Massimo Primignani,Harry L.A. Janssen,Dominique Valla,Elwyn Elias,Jaume Bosch.TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostics Factors in 124 Patients[J].Gastroenterology.2008(3)
  • 9John D.Horton,Francisco L.San Miguel,Jorge A.Ortiz.Budd–Chiari syndrome: illustrated review of current management[J].Liver International.2008(4)
  • 10Ernesto P. Molmenti,Dorry L. Segev,Aravind Arepally,Jenny Hong,Paul J. Thuluvath,Rudra Rai,Andrew S. Klein.The Utility of TIPS in the Management of Budd-Chiari Syndrome[J].Annals of Surgery.2005(6)

共引文献2

同被引文献1

引证文献1

  • 1段维佳,李淑香,吕婷婷,陈莎,冯丽娟,王晓明,欧晓娟,贾继东.结缔组织病与肝损伤[J].中华肝脏病杂志,2022,30(4):357-361.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部